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INTRODUCTION 
Interleukin 22 was first characterized in 
2000 in a screen to identify previously 
unknown cytokine transcripts induced in an 
IL-9-stimulated mouse thymic T cell. Mouse 
IL-22 shares structural similarities and 22% 
sequence homology with mouse IL-10 and 
was originally called ‘IL-10-related T cell 
inducible factor’1.1,2 .IL-22 was further 
classified as a class 2 α-helical cytokine of 
the IL-10 family of cytokines, which 
consists of IL-10, IL-19, IL-20, IL-22, IL-24 
and IL-26. IL-22 signals through a distinct 
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ABSTRACT 
Background and aims: IL-22 is an alpha- helical cytokine. IL-22 binds to a 
heterodimeric cell surface receptor composed of IL-10R2 and IL-22R1subunits. IL-22R 
is expressed on tissue cells, and it is absent on immune cells. L-22 and IL-10 receptor 
chains play a role in cellular targeting and signal transduction to selectively initiate and 
regulate immune responses. The aim of this study was to investigate the Role of 
Interleukin (IL-22) in Immune Response in human diseases. 
Methods: This study was a mini-review research to investigate the role of T helper 22 
(Th22) in immune response. 
Results: IL-22 contributes to immune disease through the stimulation of inflammatory 
responses, S100s and defensins. IL-22 also promotes hepatocyte survival in the liver and 
epithelial cells in the lung and gut similar to IL-10. In some contexts, the  
pro-inflammatory versus tissue-protective functions of IL-22 are regulated by the often 
co-expressed cytokine IL-17A. IL-22 confirms regulation of antimicrobial proteins. 
Targeting the IL-22–IL-22R pathway may yield new therapeutic potential for the 
treatment of certain human diseases. 
Conclusion: IL-22 is expressed constitutively by LTi-like cells within the small intestine, 
a tissue that is under the careful immune balance between inflammation and tolerance. 
Gaining a better understanding of the expression and role of IL-22 in health and disease 
is important for development of IL-22 as a potential drug target IL-22 is expressed 
constitutively by LTi-like cells within the small intestine, a tissue that is under the careful 
immune balance between inflammation and tolerance. Obtaining a better understanding 
of the expression and role of IL-22 in health and disease is important for development of 
IL-22 as a potential drug target. 
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class-2 receptor (IL-22R) composed of the 
subunits IL-22R1 (IL-22RA1) and IL-10R2 
(IL-10RB2), which are independently shared 
with IL-20 and IL-24 and with IL-10 and  
IL-26, respectively. IL-22 at first binds to 
IL-22R1, and then the IL-22–IL-
22R1complex binds IL-10R2 to propagate 
downstream signals.
1
 In recent years in 
many studies show that cytokines like  
IL-22, IL-17A, and IL-17F play a major role 
in both the defence against certain microbes 
and the development and maintenance of 
chronic inflammatory diseases. These 
mediators are often secreted by 
subpopulations of T-helper cells called Th17 
cells and Th22 cells, respectively.
1,2
 Similar 
to other members of the IL-10 family, IL-22 
uses the Jak-STAT signal transduction 
pathway, inducing phosphorylation of the 
kinases Jak1 and Tyk2 and the STAT1, 
STAT3 and STAT5 transcription factors.
2
 
IL-22 is known to be expressed in many 
chronic inflammatory conditions, including 
psoriasis and rheumatoid arthritis, and it’s 
up-regulation often correlates with disease 
activity. IL-22 is known to be protective in 
the gastrointestinal tract in inflammatory 
bowel disease but may mediate either 
harmful or helpful inflammatory responses 
in different models of intestinal infection.
3
 
IL-22 is central to host protection against 
bacterial infections at barrier sites. Both 
innate lymphoid cells (ILCs) and T cells 
produce IL-22. However, the specific 
contributions of CD4+ T cells and their 
developmental origins are unclear. The 
enteric pathogen Citrobacter rodentium 
induced sequential waves of IL-22-
producing ILCs and CD4+ T cells that were 
each critical to Host Defense during a 
primary infection.
4
 Termed ‘Th22’ cells, 
these cells express the chemokine receptor 
CCR6, and the skin-homing receptors CCR4 
and CCR10, allowing for localization to the 
skin. The Th22 clones continue to express 
IL-22 and not the other cytokines associated 
with these Th subsets. Th22 cells appear to 
be important for skin homeostasis and in 
inflammation as the Th22 cell population is 
increased in psoriasis patients.
5 
These 
findings establish Th22 cells as an important 
component of mucosal antimicrobial Host 
Defense. In particular, the effectors 
cytokines IL-17 and IL-22, which are 
produced by the T-helper-17-cell subset, are 
emerging as crucial regulators of 
antimicrobial-peptide production in the gut 
and the lungs. This suggests that Th22 
lineage and its cytokines have important 
roles in skin and mucosal immunity. 
IL-22 affects an acute phase response, 
implicating a role for IL-22 in mechanisms 
of inflammation. IL-22 requires the presence 
of the IL-22 receptor (IL-22R) and IL-10 
receptor 2 (IL-10R2) chains, two members 
of the class II cytokine receptor family 
(CRF2), to affect the signal transduction 
within a cell. Through activation of  
Stat3-signaling cascades, the cytokine 
induces proliferative and anti-apoptotic 
pathways, as well as anti-microbial 
molecules, that help to prevent the tissue 
damaging and aid in its repairing.
5
 IL-22 is 
expressed by both the adaptive arm of the 
immune system, such as CD4 T-cell subsets, 
as well as by innate lymphocytes, including 
NK cells and lymphoid tissue inducer (LTi) 
cells.
6
 IL-22 plays an important role in 
inflammation, including chronic 
inflammatory diseases and infectious 
diseases.
7
 The maintenance of barrier 
function at exposed surfaces of the 
mammalian body is essential for limiting 
exposure to environmental stimuli, 
preventing systemic dissemination of 
commensal and pathogenic microbes and 
retaining normal homeostasis of the entire 
body. Indeed, dysregulated barrier function 
is associated with many infectious and 
inflammatory diseases, including psoriasis, 
influenza, inflammatory bowel disease and 
human immunodeficiency virus, which 
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collectively afflict millions of people 
worldwide.
8
 Effective host protection is 
characterized by integrated responses of 
innate and adaptive arms of immunity. At 
barrier sites (e.g., skin, respiratory, and 
intestinal tracts), production of IL-22 by 
both innate and adaptive lymphoid cells is 
important in Host Defense through its 
actions on epithelial cells.
9
 
IL-22 is expressed by cells of the innate 
and adaptive immune responses in many 
mouse disease models. IL-22 seems to act 
exclusively on non-hematopoietic cells, with 
basal IL-22R expression in the skin, pancreas, 
intestine, liver, lung and kidney.
9-10
 Ligation 
of IL-22R modulates the expression of many 
genes, including those encoding molecules 
involved in chemotaxis, proliferation, an 
acute-phase response, innate immunity and 
inflammation. Therefore, it is perhaps not 
surprising that with the development of 
reagents to ablate the IL-22–IL-22R pathway, 
IL-22 was found to have critical roles in 
regulating host defence, tissue homeostasis 
and inflammation, in particular at barrier 
surfaces.
11
 Initial studies characterizing the 
functions of IL-22 showed that stimulation of 
keratinocytes with IL-22 resulted in marked 
induction of genes encoding proteins involved 
in antimicrobial host defence, including 
S100A7, S100A8, S100A9, β-defensin-2 and 
β-defensin-3 (Figure 1). Although ILCs are a 
critical source of IL-22 during mucosal 
infection, less is known regarding specific 
contributions of IL-22 produced by CD4+ T 
cells. The relative contribution of ILCs and 
CD4+ T cells in host protection against the 
enteric bacterial pathogen Citrobacter 
rodentium has been examined. ILC-derived 
IL-22 induced by IL-23 is critical to curb 
bacterial loads pending development of 
pathogen-induced CD4+ T cells, but not 
strictly dependent on IL-23.
12
 The 
transcriptome of Th22 cells differed 
significantly from Th17 cells and both AhR 
and T-bet were required for optimal IL-22 
production by Th22 cells and their host-
protective function.
13
 These findings identify 
Th22 cells as important contributors to 
mucosal host defence and suggest overlap 
between the functional programming of these 
cells with that of the recently described subset 
of Th17 cells proposed to be key contributors 
to autoimmune disease.
14 
 
 
Figure 1: The role of IL-22 and IL-17A/IL-17F during mucosal infections. MC mast cell, 
macrophage (Mɸ). DC dendritic cell. L lymphocyte 
N: neutrophile, T: Tcell, FB: fibroblast. 
 
Subsequent studies have also shown that 
the induction of two intestinal antimicrobial 
peptides, RegIIIβ and RegIIIγ, is also 
dependent on IL-22 production, and 
stimulation of airway epithelial cells with  
IL-22 results in the upregulation of many 
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genes encoding molecules involved in 
mammalian Host Defense against bacterial 
infection, including the chemokines CXCL1, 
CXCL5 and CXCL9 and the cytokines IL-6 
and G-CSF.
15
 IL-22 act synergistically or 
additively with IL-17A, IL-17F or tumour 
necrosis factor (TNF) to promote the 
expression of many of the genes that encode 
molecules involved in host defence in the skin 
airway or intestine.
16
 Demonstrating the 
functional importance of IL-22 in promoting 
barrier immunity, IL-22 is essential for host 
protective immunity to the extracellular Gram-
negative pathogens of Klebsiellap neumoniae 
in the lung and Citrobacter rodentium in the 
intestine .
14,16
 IL-22 is critical for limiting 
bacterial replication and dissemination, 
probably in part by inducing the expression of 
antimicrobial peptides from epithelial cells at 
these barrier surfaces. The influence of IL-22 
on the elicitation of host protective immunity 
is dependent on the pathogen, as IL-22 seems 
to have no substantial role in host defence 
after infection with Mycobacterium 
tuberculosis, Mycobacterium avium, Listeria 
monocytogenes or Schistosoma mansoni.
16,17
 
IL-22 may not be required for immunity to 
these specific infectious agents because, 
unlike C. rodentium or K. pneuomiae, these 
pathogens do not intimately associated with 
the barrier surface or selectively induction of 
functional or pathological changes in epithelial 
cells.
18
 Furthermore, although it does not have 
a direct role in immunity, IL-22 seems to 
promote intestinal inflammation after oral 
infection with Toxoplama gondii which 
demonstrates that some infectious agents elicit 
a non-beneficial pro-inflammatory IL-22-
dependent response.
19
 Although this is still in 
the early stages of investigation, IL-22 does 
not seem to have a substantial direct role in 
immunity to viral pathogens. For example,  
IL-22 deficiency does not influence the 
outcome of influenza infection.
20
 However, 
IL-22 may have an important role in providing 
protective innate immunity when the adaptive 
immune system is impaired, such as after 
infection with human immunodeficiency 
virus. This is evident in immunity to gastric 
Candida albicans, in which IL-22 promotes 
protective immunity to infection when 
immunity dependent on T helper type 1 (TH1) 
cells is impaired. In animal models of 
candidiasis, there are conflicting reports as to 
the importance of IL-22 to pathogenesis.
21
 In 
contrast, oral inoculation of the parasite into 
IL-22-deficient mice results in less disease 
pathology in the small intestine compared 
with wild-type controls. Thus, IL-22 is 
pathogenic in the course of T. gondii infection 
in the GI tract, but not other tissues.
21
 When 
infection by the parasite Toxoplasma gondii is 
introduced via the peritoneal cavity or the 
bloodstream, IL-22 does not play a detectable 
role in its pathogenesis, including parasite 
loads in the brain and liver lesions.
21
 IL-22 can 
be an inflammatory factor and mediate disease 
in the GI tract.
22
 IL-22 helps to prevent 
dissemination of pathogenic bacteria, such as 
Klebsiella pneuomniae in the lung, or 
enteropathogens, including Citrobacter 
rodentium and Salmonella enterica serotype 
Typhimurium, in the GI tract; thereby it limits 
bacterial growth.
23
 Additionally, IL-22 aids in 
the elimination of pathogens by inducing 
different anti-microbial proteins (RegIIIβ and 
RegIIIγ). Although human data indicating a 
role for IL-22 in infection are sparse, Patients 
with autoimmune polyendocrine syndrome 
type I have a high rate of chronic 
mucocutaneous candidiasis.
23
 In the study of 
Puel et al. It has been showed that these 
patients have high levels of auto-antibodies to 
IL-17A and IL-22, in effect leading to 
cytokine neutralization and suggesting that 
these cytokines are important for controlling 
yeast infections.
24
 
Augmented expression of IL-22 has been 
documented in several disease states and, 
furthermore, spontaneous mutations arising in 
the human population that affect the IL-22–
IL-22R pathway correlate with defects in 
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barrier immunity. These data suggest that 
targeting the IL-22–IL-22R pathway may 
yield new therapeutic potential for treatment 
of certain human diseases.
25
 IL-22 expression 
is detected in many inflammatory and 
infectious human diseases. For example, 
higher concentrations of IL-22 derived from 
Th17 cells are observed in the peripheral 
blood and tissues of patients with psoriasis or 
arthritis, and on the basis of preclinical model 
studies, it is predicted that IL-22 promotes 
pathological inflammation in these disease 
settings.
18,25
 In contrast to its concentration in 
psoriasis, higher concentrations of IL-22 from 
Th22 and TC22 cells are observed in the 
inflamed skin of patients with atopic 
dermatitis.
26
 IL-22 concentrations are also 
higher in the peripheral blood and intestine of 
patients with inflammatory bowel disease. 
Although IL-22 is tissue protective in mouse 
models its role in human intestinal 
inflammation, as IL-22 expression correlates 
with  
pro-inflammatory gene expression.
27
 Infection 
with Leishmania donovani, which causes a 
lethal visceral disease, is associated with Th17 
cell expression of IL-22 and is also positively 
correlated with disease protection. Further, 
patients with cystic fibrosis who have 
exacerbated infection with Pseudomonas 
aeruginosa have more T cell secretion of IL-
22 in lung-draining lymph nodes.
28 
This 
induction of IL-22 expression in infectious 
settings is consistent with its identified role in 
mouse models for the promotion of immunity 
at barrier surfaces. Thus, most reports have 
examined T cell expression of IL-22 in human 
disease; however, given the characterization 
and critical importance of IL-22 expression by 
innate cells, it will also be important to 
examine innate sources of IL-22, such as 
ILCs, in future studies.
27-28
 
IL-22, IL-17A and IL-17F have been 
shown to cooperate in the induction of 
antimicrobial-protein expression, such as 
HBD2, HBD3 and calgranulin, by human skin 
keratinocytes and bronchial epithelial 
cells.
25,28 
(Figure 2). Furthermore, in mouse 
tracheal epithelial cells, IL-22 and IL-17 
synergistically induce lipocalin-2 expression, 
and this induction is required for antimicrobial 
activity against the Gram-negative pathogen 
Klebsiella pneumonia, the mechanism of 
synergism between IL-17 and IL-22 is yet to 
be defined, but may be the result of a 
convergence of the STAT3 (signal transducer 
and activator of transcription 3) and NF-κB 
signalling pathways, which are induced 
downstream of the IL-22 and IL-17 
receptors,respectively.
29
 Exactly how IL-22-
induced STAT3 signalling converges with the 
ACT1–PI3K–NF-κB pathway to cooperate 
with IL-17 in antimicrobial-protein induction 
is unclear. However, it is possible that this 
synergy occurs at the level of downstream 
kinases that have been implicated in both IL-
22R and IL-17R signalling, including the 
mitogen-activated protein kinases and the JUN 
N-terminal kinases.
30
 In the mouse 
gastrointestinal tract, IL-22 was recently 
shown to be required for the induction of 
expression of the C-type lectins regenerating 
protein 3β (REG3β) and REG3γ following 
challenge with Citrobacter rodentium. 
Consistent with this, also showed that IL-22-
deficient mice are highly susceptible to 
infection with C. rodentium can be rescued 
from a lethal challenge through the 
administration of recombinant human or 
mouse REG3γ. REG3γ is a soluble C-type 
lectin that is produced by Paneth cells and has 
direct antimicrobial activity against Gram-
positive bacteria by interacting with bacterial 
peptidoglycan.
31
 REG3γ is not known to have 
direct antimicrobial activity against Gram-
negative organisms, although commensal flora 
can induce its expression. In addition, the 
study by Zheng et al. suggested that REG3γ 
has antimicrobial activity (albeit not directly 
microbicidal) against certain pathogenic 
Gram-negative bacteria.
29
 Pathogenic  
Gram-positive bacteria, such as Listeria 
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monocytogenes, can induce REG3γ 
production in a MyD88- dependent manner, 
which indicates that TLR or IL-1R signalling 
might be involved in REG3γ expression and 
regulation.
31 
The effects of IL-22 in this model 
imply that this cytokine has a role in 
inflammation, although this remains a 
controversial issue. A role for IL-22-driven 
TH17-cell-mediated antimicrobial-protein 
expression in inflammatory disease is most 
apparent in the skin. Antimicrobial peptides 
are highly expressed in the skin of patients 
with psoriasis.
31
 The preferred action of 
REG3γ against Gram-positive or commensal 
organisms presents an intriguing possibility: 
the balance of inflammation and tolerance 
against a constant presence of bacteria in the 
gut could be linked to differential cytokine-
mediated regulation of antimicrobial 
proteins.
32
 IL-22 strongly induces both the 
proliferation of keratinocytes and the 
expression of antimicrobial proteins, such as 
S100A7. Moreover, neutralization of IL-22 
can reduce cutaneous acanthosis (thickening 
of the skin) in models of psoriasis.
33
 A role for 
TH17 cells in antimicrobial responses is also 
supported by the finding that patients with 
mutations in STAT3 that cause Job’s 
syndrome (hyper-IgE syndrome) and 
increased susceptibility to cutaneous 
infections with Staphylococcus aureus and  
C. albicans lack antigen-specific Th17 cells in 
the peripheral blood.
34
 Curiously, these 
patients have an exaggerated Th2-cell-
associated hyper-IgEsyndrome.
33-34
 In 
individuals with atopic dermatitis, the  
Th2-type cytokines IL-4 and IL-13 are highly 
expressed in the skin.
35 
This may explain the 
frequent occurrence of S. aureus infections in 
patients with atopic dermatitis. IL-4 and IL-13 
can activate STAT6, as well as SOCS1 and 
SOCS3, which then inhibit both tumour 
necrosis factor (TNF) and interferon-γ (IFNγ) 
mediated induction of HBD2, and HBD3 
expression by keratinocytes.
36
 Further work is 
required to determine the role of IL-22 (or 
other activators of STAT3) in Job’s syndrome, 
and whether myeloid-cell or epithelial-cell 
expression of STAT3 contributes to the 
clinical phenotype of this syndrome, including 
the high IgE levels and susceptibility to S. 
aureus and C. albicans infections.
37 
 
 
 
Figure 2: Cytokine networks and antimicrobial peptides at epithelial-cell surfaces 
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In response to bacterial infection, the 
interleukin-1 (IL-1) family cytokines, such 
as IL-1β, potently induce the expression of 
antimicrobial proteins by the epithelium.  
IL-1β, together withIL-6 and IL-23, can also 
induce the differentiation of T helper 17 
(TH17) cells, which produceIL-17A, IL-17F 
and IL-22. These cytokines further induce 
antimicrobial-protein expression by the 
epithelium. IL-17A can also induce the 
production of CC-chemokine ligand 20 
(CCL20), which has antimicrobial activity, 
recruits dendritic cells and increases the 
production of CXC chemokine receptor 2 
(CXCR2) ligands that are important in 
neutrophil recruitment. This response is 
beneficial to the host during an acute 
infection. However, in autoimmune diseases 
(such as psoriasis) cationic antimicrobial 
peptides, which are present at high levels, 
can interact with negatively charged DNA 
that is released from dying cells (cell death 
occurs as a result of increased cell turnover 
during inflammation). Antimicrobial-
peptide–DNA complexes can amplify 
inflammation in the skin by activating Toll-
like receptor 9 (TLR9) signalling. 
 
CONCLUTION 
There exist so many outstanding 
questions regarding IL-22 and inflammation. 
Most in vivo studies have not elucidated  
IL-22-expressing cell subset which mediates 
the observed effects. For example, Th17 
cells have been shown to be able to provide 
protection against hepatitis. Other studies 
have distinguished between innate and 
adaptive immune system-derived IL-22 by 
comparing models between 
immunocompetent mice and mice with 
deficient adaptive immune responses. 
Further examination pin-pointing the role of 
different IL-22-expressing subsets will allow 
us for better understanding this cytokine. 
The role of IL-22 not under the 
inflammatory conditions, but instead during 
homeostasis needs to be more closely 
examined. IL-22 is expressed constitutively 
by LTi-like cells within the small intestine, a 
tissue that is under the careful immune 
balance between inflammation and 
tolerance. Gaining a better understanding of 
the expression and role of IL-22 in health 
and disease is important for development of 
IL-22 as a potential drug target. An 
increasing number of reports of human- and 
mouse-based studies have highlighted the 
fact that IL-22–IL-22R interactions are an 
integral pathway through which cells of the 
innate and adaptive immune responses 
regulate host defence, inflammation and 
tissue homeostasis at barrier surfaces. 
Although important advances have been 
made in understanding the factors that 
influence the expression, regulation and 
functions of IL-22 and IL-22R, the 
development, plasticity and cell-lineage 
relationships of innate sources of IL-22 in 
mouse and human diseases remain unclear. 
In addition, future challenges include 
defining the context-dependent functions of 
IL-22 expression in tissue inflammation and 
repair, including the effect of microbial 
communities at barrier surfaces and the 
spatial and temporal co-expression of other 
pro-inflammatory or regulatory cytokines. 
Advancing knowledge in these areas will aid 
in the design of therapeutic treatments 
targeting the IL-22–IL-22R pathway for the 
treatment of persistent infections, chronic 
inflammation and autoimmune diseases. 
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